Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goki Suda

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Seminars in Oncology|June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world populationFrancesco Vitiello, Toshifumi Tada, Goki Suda, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
Journal of Gastroenterology|July 19, 2018
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infectionGoki Suda, Masayuki Kurosaki, Jun Itakura, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Restoration of the gut-microbiota-liver axis after hepatitis C virus eradicationTakako Inoue, Jiro Nakayama, Hiroshi Mori, et al.
Liver Cancer|January 2, 2023
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Seminars in Oncology|June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world populationFrancesco Vitiello, Toshifumi Tada, Goki Suda, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
Journal of Gastroenterology|July 19, 2018
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infectionGoki Suda, Masayuki Kurosaki, Jun Itakura, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Restoration of the gut-microbiota-liver axis after hepatitis C virus eradicationTakako Inoue, Jiro Nakayama, Hiroshi Mori, et al.
Liver Cancer|January 2, 2023
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 15